One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Each component individually is stable. Instability emerges at the level of their integration. When environmental complexity increases, planners expand more nodes. When ambiguity grows, the Behavior ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Abstract: This paper presents a comparative study of two parameter identification methods: an algebraic approach based on the direct manipulation of the system’s differential equations and the ...

Recursion Pharmaceuticals utilizes a proprietary operating system (OS) and an AI-powered algorithm that continuously runs virtual experiments, testing compounds against a library of human genes to ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...